Introduction
Surface dose from a photon beam during radiotherapy (RT) treatments cannot be ignored and does contribute to the major extent. The surface dose results from the scatter from the machine head as well as the patients. The machine head design, internal components, and the treatment geometry play an important role in contributing the surface dose to the patient. The effect of surface dose from different clinical setups is discussed elsewhere (1). The surface dose from IMRT has also been reported (2). The superficial dose for the patients treated with Tomotherapy has been studied (3).
The TomoTherapy system is a relatively new RT treatment modality, which has come into use in the treatment of various malignant lesions. This system offers a unique way of delivering intensity modulated radiation therapy (IMRT) as well as having the benefit of image-guided radiation therapy (IGRT). The TomoTherapy unit consists of a linear accelerator (linac) mounted onto a computed tomography (CT) ring gantry. The details about the design and the characteristics of Tomotherapy have been discussed (4) (5) . TomoTherapy is currently being used primarily to treat a variety of deep-seated tumors. As the TomoTherapy system does not have an electron beam modality, as do traditional linacs, it is important to know TomoTherapy's ability and potential for treating superficial diseases, which are often treated with electron beams. If helical TomoTherapy is to be used as a superficial treatment, it is essential that the dose to the surface must be estimated. Therefore, it was decided to estimate the surface dose from a static TomoTherapy beam (i.e., the gantry and table are stationary). Thus, this work concentrates on measuring the surface dose from a static TomoTherapy beam at normal incidence. In addition, the goal was to compare this surface dose to 6 MV photon beam from the linac. Further measurements were extended to the surface dose estimation for telecobalt machines as well. Thermoluminescent dosimeters (TLD) were used to measure the surface dose.
Methods and Materials
Several pieces of phantom material were used to create depth for the measurements. Both Plastic Water ® and StanGantry Angle 0º 
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dard Imaging Virtual Water ® slab phantoms were used. The Plastic Water ® slab phantoms used were 30 cm × 30 cm and ranged from 0.1 to 0.5 cm in thickness with the density of this material to be 1.014 g·cm 3 ± 1.1%. The Virtual Water ® slab phantoms used were 55 cm × 15 cm and were ranged from 1 to 5 cm thick. The manufacturer states that the density of this material is 1.03 g/cm 3 . They also quote the error in thickness to be ± 0.15 mm.
Prior to each irradiation, TLD-100 (LiF:Mg,Ti) powder (The Harshaw Chemical Co. Solon, Ohio, USA) was annealed using a thermal cycle: 400º C (±5º) for 1h-cooling for 5 min -100ºC for 2 h in a Programmable Muffle Furnace (Model-126, Fisher Scientific Co. Pittsburgh, PA, USA) and then cooled to normal room temperature. For annealing, the TL powder was placed inside a glass petty dish with cover. Rexon UL-320 TLD Reader (TLD systems Inc. USA) was used to record TL output at maximum acquisition temperature of 280º C using constant heating rate of 14º C/sec.
For measurements using TLD, about 40 mg of the freshly annealed TLD-100 powder was packed in square polyethylene pouch (1cm × 1cm) as shown in Figure 2 . This TL pouch was placed in the phantom at dmax along the central axis of the beam and was irradiated for 100 MUs. The TL output of about 10 mg powders was recorded using Rexon TLD reader and this way four readings were obtained from each TL pouch. The mean value of net TL output per unit weight (nC/mg) of these four readings was used for calculation. The uncertainty in TLD-100 powder measurements was ± 2%.
Constant time gap of 24h was maintained between irradiation and read out. Dose response curve for the TLD-100 powder was generated in 60 Co gamma ray beam (Equinox 80, MDS Nordion, Canada) and was found linear in the range of 0.5-4.0 Gy. One packet was not irradiated to determine the background signal.
For surface dose measurements with Tomotherapy, the TLDs were placed at various depths (ranging from surface to 20 cm) in virtual water slabs for a field size of 5 cm × 40 cm at source to surface distance (SSD) 85 cm. This setup ( Figure  3 ) helped us to measure the central axis depth dose (CADD). The phantom and TLDs were placed on the TomoTherapy couch so that the TLD was at the virtual isocenter position (70 cm from the axis of rotation, in the -Y direction). The fixed position green lasers are used to setup this position. Dose was measured on the central axis for static and normally incident TomoTherapy beams. The delivery system was operated in 'physics' mode, which allows beams to be delivered while the gantry and table are stationary. The procedure with all central multileaf collimator (MLC) leaves open for 10 seconds was used to irradiate the TLDs. Subsequently, the surface dose measurements were also carried for four linear accelerators. Clinac 6EX, Clinac 2100CD, and Clinac 2100C (Varian Medical Systems, Palo Alto, USA) were used for these measurements. The TLDs were placed in plastic water slabs at the above mentioned depths for 10 cm × 10 cm field size at SSD 100 cm for 6 MV photon beam. TLDS were also irradiated for Primus (Siemens Medical Systems, Concord, USA) for same field size. The irradiation was performed for 100 monitor units (MU). Phantom material (7 cm) was placed beneath the TLDs to serve as backscatter material.
Further, surface dose was measured for five telecobalt machines. Equinox-80, Elite-80, Th-780C, Th-780 (Best Theratronics Ltd., Ottawa, Canada), and Bhabhatron-II (Panacea Medical Technologies Pvt. Ltd., Bangalore, India) were used for this measurement. The surface dose was measured for 10 cm × 10 cm field size at SSD 80 cm in plastic water slabs. TLDs were placed at the surface and at 5 mm depth in plastic water slabs with 7 cm backscatter.
The un-normalized percentage CADD curves were plotted against the depth and the depth of dose maximum (Dmax) was estimated for each machine. The values were then normalized to Dmax and the normalized CADD values were recorded for individual machine. The surface dose was estimated from these data. The ratio of ionization at 20 cm to 10 cm was also estimated.
Results
The Dmax of 1.1 cm was obtained for 6 MV beam from Tomotherapy while the Dmax for Clinac 6EX, Clinac 2100CD, and Clinac 2100C was found to be 1.42, 1.5, and 1.5 cm, respectively. Similarly, the Dmax for Primus linear accelerator was obtained as 1.5 cm as well. Figure 4 shows the comparison of the normalized CADD values for Tomotherapy and four linear accelerators. The CADD values were normalized to the reference depth of 1.5 cm for linac while it was normalized at 1.1 cm for Tomotherapy. The results depicted a good agreement among the five machines.
For Tomotherapy 6 MV beam the surface dose was estimated as 32% while it was 35%, 33%, and 36% for Clinac 6EX, Clinac 2100CD, and Clinac 2100C linear accelerators, respectively. Similarly, the surface dose for 6 MV beams from Primus linear accelerator was estimated as 35%. Surface doses from telecobalt machines Equinox-80, Elite-80, Th-780C, Th-780, and Bhabhatron-II was found to be 30%, 29.1%, 27.8%, 29.3%, and 29.9%, respectively. Thus, measured surface doses from linear accelerator, tomotherapy, and telecobalt showed comparable results.
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The ratio of ionization at 20 cm to 10 cm (D20/D10) was calculated and found to be 0.52, 0.55, 0.55, 0.53, and 0.54 for Tomotherapy, Clinac 6EX, Clinac 2100CD, Clinac 2100C, and Primus linear accelerator, respectively.
Discussion
This study deals with the surface dose estimation from five teletherapy machine including the unconventional treatment modality like Tomotherapy. The surface doses were also measured for telecobalt machines as well. Since the SSD from telecobalt machine (80 cm) is nearly close to Tomotherapy (85 cm), it was necessary to measure the surface dose and compare each other. The surface dose is usually measured with the parallel plate ion chamber. The ion chamber has the limitation the electrode separation that results in uncertainties in estimating the accurate surface dose and, hence, the utility of TLD become more prominent.
Dose to the skin surface in a normally incident megavoltage photon beam is the sum of two components. The first component is electrons created from photon interactions in the patient. Most of these electrons are scattered in a forward direction because they are created from primary photons traveling in a forward direction. However, some of these electrons may side scatter or back scatter to the surface. The second component of surface dose is electrons created from photon interactions prior to the patient. These electrons are created somewhere in the treatment head or the air column above the patient. They deposit their energy at the surface and superficial depths. These electrons are called contaminant electrons.
The main sources of contaminant electrons are the flattening filter and the air below it. The air produces electrons of low energies, of which the mean of the energy spectra vary from 1 to 2 MeV, depending on the nominal energy of the photon beam. The flattening filter produces a wide energy spectrum of electrons similar to the bremsstrahlung spectrum. At 6 MV, however, the air below the accelerator generates the majority of contaminant electrons.
TomoTherapy is unique in the design of its beam filtration system in the treatment head. Conventional accelerators have a flattening filter downstream of the target. The filter is used to produce a uniform photon beam at a depth of 10 cm. TomoTherapy's treatment head does not have a flattening filter. The unit does have a set of uniform thickness filters that provide electronic buildup to the monitor chambers (which monitor the output of the machine) and filter low-energy photons from the beam.
The dose measured in each TLD packet represents an average of the doses deposited within the volume of powder. Since the powder was not arranged in a monolayer within the packet, the measurement represents an average of doses obtained at different depths within the packet. Assuming the depth dose varied linearly through the packet, the measurement represents the dose at an average depth. The surface dose might be relatively more for Tomotherapy beam compared to linac. The reason may be due to the absence of flattening filter and the short treatment distance. The nominal treatment distance (NTD) for linear accelerators and tomotherapy is 100 cm and 85 cm, respectively. The shorter NTD may relatively increase the surface dose compared to the longer NTD from linear accelerators. Hence, it was necessary to take this study to quantify the surface dose from the tomotherapy unit. Being the first installation in India, this data would be useful for the future installations of tomothearpy in India. Since the maximum field size with Tomotherapy is 5 cm × 40 cm and, hence, the contribution of the surface dose is not likely to increase further. Moreover, the helical treatment delivery restricts the secondary scatter reaching to the patient.
The surface dose measured for all three Varian linacs was comparable with that of Siemens linac. The ratio of D20/ D10 was also estimated for five machines and the results are comparable. Similarly, the surface doses from all the telecobalt machines were comparable. TLD was very useful as a reliable dosimeter for surface dose estimation. Strict handling procedures of TLD were followed in the institution.
Conclusion
The results for the surface dose estimation for Tomotherapy were satisfactory and acceptable. Moreover the results were in good agreement with the surface dose measurements carried out for 6 MV photon beam from four linear accelerators and telecobalt machines from different vendors. The surface dose measurements were useful for Tomotherapy to predict the superficial dose during helical IMRT treatment.
